A win with a tenapanor combo could bode well for the project’s monotherapy chances.
With little cash in the bank and creditors soon to start pressing, a trial failure is a disaster for Viveve.
Cara Therapeutics’ stock shot up 18% today on data derisking two key projects.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Fibrogen tumbles on a confusing safety update for its most advanced project.
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.